ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)

Phase 3

Withdrawn

• Conditions: Acute Myeloid Leukemia
• Interventions: Drug: Vesanoid (ATRA); Drug: AZACITIDINE (VIDAZA); Drug: CYTARABINE

• Registration Number: NCT01067274
• Lead Sponsor: Acute Leukemia French Association

Brief Summary

A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML).

To compare the outcome of elderly patients with newly-diagnosed AML treated with standard induction chemotherapy and post-remission therapy, in only patients in CR, with either azacitidine or cytarabine combined to idarubicin +/- ATRA and salvage therapy with azacitidine combined to idarubicin +/- ATRA.

Detailed Description

Induction therapy :

First randomization (R1) at baseline : ATRA versus no ATRA.

Salvage therapy :

No conventional salvage therapy is planned. Patients who will not achieve CR, according to IWG criteria after induction will be treated with 3 courses of azacitidine and idarubicin +/- ATRA combination, if eligible for further treatment.

Followed by 3 identical courses and 6 courses of maintenance by azacitidine alone to be delivered every 28 days, in those patients reaching CR or PR after 3 courses (evaluation of response from 28 to 56 days from course 3).

Randomization R2: type of maintenance:

Response to induction will be evaluated 2 weeks after myeloid recovery, just before first consolidation course, due use of to pegfilgrastim, lenograstim or filgrastim during induction.

Responses will be classified according to the Revised Recommendations of the IWG for AML.

Patients in CR only will be subjected to a second randomization R2 as follows 6 courses of combined chemotherapy, will be delivered as outpatients, ATRA according to R1 randomization.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2010-02
• Study First Submitted: 2010-02-10
• Study First Submitted QC: 2010-02-10
• Study First Posted: 2010-02-11
• Study Start: 2010-04
• Last Update Submitted: 2015-12-29
• Last Update Posted: 2015-12-30
• Primary Completion: 2016-04

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged of 65 to 79 years
2. With a morphologically proven diagnosis of AML according to WHO classification either de novo or AML with "myelodysplasia related changes"
3. Not previously treated for AML
4. Signed informed consent.

Read More

Exclusion Criteria

1. APL in the WHO classification.
2. Ph1-positive AML or prior Ph1-positive disease
3. AML evolving from a prior MPN in the WHO 2008 classification.
4. Prior treatment with chemotherapy or radiotherapy for another tumor
5. Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
6. Prior advanced malignant hepatic tumor
7. ECOG Performance Status Score > 2
8. Creatinine level more than 2x's the upper limit of the normal range (ULN) at the laboratory where the analysis was performed, except if AML-related.
9. Total serum bilirubin more than 2x's the ULN at the laboratory where the analysis was performed, except if AML-related.
10. AST (SGOT) or ALT (SGPT) more than 2.5x's the ULN at the laboratory where the analysis was performed, except if AML-related
11. LVEF less than.55 or equivalent by doppler echocardiography
12. Known intolerance to Azacitidine, mannitol, retinoids
13. Positive serum test for HIV and HTLV-1
14. NYHA Grade 3/4 cardiac disease .
15. Severe infection at inclusion time.
16. Psychiatric disease or an history of non-compliance to medical regimens or patients considered potentially unreliable.
17. Absence of health care insurance (affiliation à un régime de Sécurité Sociale)
18. Participation to any study requiring informed consent

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
R2 Arm 1A : AZACITIDINE and ATRA	Vesanoid (ATRA)	Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
R2 Arm 2A : ATRA	Vesanoid (ATRA)	Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
R2 Arm 1A : AZACITIDINE and ATRA	AZACITIDINE (VIDAZA)	Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
R2 Arm 1B : AZACITIDINE and No ATRA	AZACITIDINE (VIDAZA)	Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
R1 Arm A : ATRA	Vesanoid (ATRA)	Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN \>1G/l over 2 days at minimum All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28
R2 Arm 2A : ATRA	CYTARABINE	Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
R2 Arm 2B : no ATRA	CYTARABINE	Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5

Primary Outcome Measures

Name	Time	Method
For randomization R1, the primary endpoint is Event-free Survival (EFS)	2-year EFS
For randomization R2, the primary endpoint is disease free survival (DFS)	2-year DFS

Secondary Outcome Measures

Name	Time	Method
Complete Response (CR) rate	2 years
Overall survival	2 years
Response rate to azacitidine idarubicin +/-ATRA combination after intensive chemotherapy failure and identification of possible predictors of response to this therapy	2 years
Assess the safety of combination ATRA + chemotherapy or idarubicin-azacitidine courses and of maintenance with azacitidine	2 years
Effects on relapse rates of ATRA and maintenance, with respect to cytogenetics risk groups, subtypes of AML and mutational status (FLT3, MLL), and biomarkers	2 years

Trial Locations

Locations (18)

CHU; 🇫🇷 Rouen, France

Hopital Percy; 🇫🇷 Clamart, France

Centre Antoine Lacassagne; 🇫🇷 Nice, France

Chu Boulogne Sur Mer; 🇫🇷 Boulogne Sur Mer, France

Hopital Pitie-Salpetriere; 🇫🇷 Paris, France

Hopital Avicenne; 🇫🇷 Bobigny, France

Chu Amiens Sud; 🇫🇷 Amiens, France

CH; 🇫🇷 Versailles, France

Ch Sud Francilien; 🇫🇷 Corbeil Essonnes, France

Hopital Henri Mondor; 🇫🇷 Creteil, France

Necker Hospital; 🇫🇷 Paris 15, France

Ch Dunkerque; 🇫🇷 Dunkerque, France

Hopital Edouard Herriot; 🇫🇷 Lyon, France

Hopital Saint-Louis; 🇫🇷 Paris, France

Ch Rene Dubos; 🇫🇷 Pontoise, France

CNLCC; 🇫🇷 Saint-Cloud, France

St Antoine Hospital; 🇫🇷 Paris, France

IGR; 🇫🇷 Villejuif, France